Crowley, Michael J. P.
Bhinder, Bhavneet
Markowitz, Geoffrey J. http://orcid.org/0000-0003-3915-8078
Martin, Mitchell
Verma, Akanksha
Sandoval, Tito A. http://orcid.org/0000-0003-2705-5282
Chae, Chang-Suk
Yomtoubian, Shira
Hu, Yang http://orcid.org/0000-0002-6348-874X
Chopra, Sahil http://orcid.org/0000-0002-5837-5169
Tavarez, Diamile A.
Giovanelli, Paolo http://orcid.org/0000-0002-5799-6721
Gao, Dingcheng http://orcid.org/0000-0002-3903-2603
McGraw, Timothy E. http://orcid.org/0000-0001-9748-263X
Altorki, Nasser K. http://orcid.org/0000-0001-9754-9945
Elemento, Olivier http://orcid.org/0000-0002-8061-9617
Cubillos-Ruiz, Juan R. http://orcid.org/0000-0002-4267-4893
Mittal, Vivek http://orcid.org/0000-0002-4764-7413
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA217032-01)
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (LC180486, LC180486)
Article History
Received: 24 September 2021
Accepted: 13 December 2022
First Online: 9 January 2023
Competing interests
: J.R.C.-R. is a scientific consultant for NextRNA Therapeutics, Inc. and Autoimmunity Biologic Solutions, Inc, and holds patents on IRE1α modulation for the treatment of disease. O.E. is supported by Janssen, J&J, Astra-Zeneca, Volastra, and Eli Lilly research grants. He is a scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics, and One Three Biotech and a paid scientific advisor to Champions Oncology and Pionyr Immunotherapeutics. The remaining authors declare no competing interests.